The implications of model-informed drug discovery and development for tuberculosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The implications of model-informed drug discovery and development for tuberculosis

Published:2017-03 Issue:3 Volume:22 Page:481-486
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Muliaditan Morris,Davies Geraint R.,Simonsson Ulrika S.H.,Gillespie Stephen H.,Della Pasqua Oscar

Funder

Innovative Medicines Initiative Joint Undertaking

European Union's Seventh Framework Program

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference32 articles.

1. Challenges in tuberculosis drug research and development;Ginsberg;Nat. Med.,2007

2. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis;Gillespie;N. Engl. J. Med.,2014

3. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients;Jawahar;PLoS ONE,2013

4. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis;Jindani;N. Engl. J. Med.,2014

5. A four-month gatifloxacin-containing regimen for treating tuberculosis;Merle;N. Engl. J. Med.,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacometrics in tuberculosis: progress and opportunities;International Journal of Antimicrobial Agents;2022-09

2. Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection;European Journal of Pharmaceutical Sciences;2022-06

3. Mechanistic modelling of enzyme‐restoration effects of new recombinant liver‐targeted proteins in acute intermittent porphyria;British Journal of Pharmacology;2022-03-21

4. Bacterial growth dynamics and pharmacokinetic–pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice;British Journal of Pharmacology;2021-12-27

5. Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era;Frontiers in Microbiology;2021-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3